Workflow
PREDATOR® platform
icon
Search documents
Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference
Globenewswire· 2025-05-29 12:00
Core Insights - Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company focused on developing conditionally activated therapeutics to stimulate the immune system for cancer treatment [3] - The company will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 5, 2025, featuring CEO Daniel J. Hicklin and CMO Randi Isaacs [1][2] Company Overview - Werewolf Therapeutics leverages its proprietary PREDATOR® platform to create therapeutics that activate selectively in the tumor microenvironment while remaining inactive in peripheral tissues [3] - The company's advanced clinical candidates include WTX-124 and WTX-330, which are conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) molecules, respectively, aimed at treating solid tumors [3] - WTX-124 is being advanced in multiple tumor types both as a single agent and in combination with immune checkpoint inhibitors, while WTX-330 is being explored for various tumor types and Non-Hodgkin Lymphoma [3]
Werewolf Therapeutics to Participate in Upcoming Investor Conferences
Globenewswire· 2025-05-05 12:00
Company Overview - Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company focused on developing conditionally activated therapeutics to stimulate the immune system for cancer and other immune-mediated conditions [3] - The company utilizes its proprietary PREDATOR® platform to create molecules that selectively activate in the tumor microenvironment while remaining inactive in peripheral tissues [3] Product Development - Werewolf's advanced clinical stage product candidates include WTX-124 and WTX-330, which are conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules, respectively [3] - WTX-124 is being advanced in multiple tumor types both as a single agent and in combination with an immune checkpoint inhibitor, while WTX-330 is being developed for multiple tumor types or Non-Hodgkin Lymphoma as a single agent [3] Upcoming Events - Management will participate in the Citizens Life Sciences Conference on May 8, 2025, at 10:00 am ET in New York [2] - Management will also participate in the Bank of America Securities 2025 Health Care Conference on May 14, 2025, at 3:15 pm PT in Las Vegas [2] - Live webcasts for these events will be available, with archived replays accessible for approximately 90 days [2]